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Background: The combination of Pegylated Interferon-alpha (PEG-IFN-α) and ribavirin is the current standard of
care for the treatment of HCV infection. Unfortunately, IFN-α may lead to the induction or exacerbation of auto-
immune diseases, such as psoriasis, thyroiditis, systemic lupus erythematosus and, rarely, rheumatoid arthritis (RA).
Case presentation: We report the case of a man affected with chronic hepatitis C (CHC) due to HCV genotype 3a
infection, who developed RA after a complete course of PEG-IFN-α and ribavirin. Nine weeks after cessation of anti-
viral treatment, the patient developed symmetrical polyarthritis, with pain and edema in the wrists, knees, shoulders
and metacarpophalangeal joints; magnetic resonance imaging detected initial bone erosions with juxta-articular
osteopenia in wrist, knee and hand joints. Anti-cyclic citrullinated peptide (anti-CCP) antibodies were positive.
Conclusions: Autoimmune diseases, including RA, may occur when treating chronic hepatitis C with PEG-IFN-α and
ribavirin; therefore, a close surveillance for the occurrence of autoimmune phenomena should be suggested in the
setting of HCV management.Background
Hepatitis C Virus (HCV) is the most common cause of
cirrhosis and hepatocellular carcinoma (HCC) in West-
ern countries, both in the immunocompetent and in the
immunodeficient host [1,2].
The combination of Pegylated Interferon-alpha (PEG-
IFN-α) and ribavirin is the current standard of care to
treat HCV infection [3]; unfortunately, this therapy is ac-
companied by a wide variety of possible side effects, which
may lead to early or late treatment discontinuation [4].
Ongoing studies have focused on new therapeutic mole-
cules and strategies, in order to find IFN-free regimens,
with a better tolerability profile [5,6].
Autoimmune phenomena have been frequently re-
ported in patients with chronic HCV infection receiving
IFN-α treatment [7-9]. The spectrum of autoimmune
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distribution, and reproduction in any mediumserum autoantibodies up to development of overt auto-
immune diseases [9,10]. Although rheumatoid arthritis
(RA) is one of the most common autoimmune diseases,
the development of RA after IFN-α plus ribavirin has
rarely been reported [11-14] (Table 1). We report the
case of a 53-year-old man with Chronic Hepatitis C
(CHC), who developed RA after a complete course of
PEG-IFN-α and ribavirin therapy.
Case presentation
A 53-year-old man, working as a male nurse in a local
hospital, was diagnosed with HCV infection after detec-
tion of abnormal liver function tests in 2010. His past
medical history was unremarkable. He denied intravenous
drug abuse or history of blood transfusions. In January
2011 he presented to the Outpatient Infectious Diseases
clinic for evaluation: he was in good clinical condition and
did not complain at all of articular or muscular pain; liver
was palpable 3 cm below the right costal margin. No
splenomegaly was present. His Body Mass Index was 27.
HCV RNA was 660,000 IU/mL (TaqMan Real Time PCR);tral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Previous literature reports of IFN-α-induced rheumatoid arthritis in patients with CHC
Age Sex Treatment Onset Biochemical
abnormalities
Treatment and outcome
Sood et al. [12] 47 W Recombinant
IFN-α-2b + RIB
20 weeks after starting
antiviral therapy
ESR↑, ANA-, RF+ NSAIDs
No interruption of antiviral therapy
Ionescu et al. [13] 40 W PEG-IFN-α-2b +
RIB







10 months after re-
treatment for relapsing
CHC
HLA B27- HLA DR3/4+ Regression after cessation of antivirals
Yang et al. [14] 54 M PEG-IFN-α-2a +
RIB
18 weeks after starting
antiviral therapy
ESR↑, ANA-, RF-, Anti-
CCP Ab+, CRP ↑,
Ibuprofen, celecoxib and tramadol, then switch
to hydroxychloroquine and sulfasalazine





Anti-CCP Ab: anti-cyclic citrullinated protein antibody; ANA: antinuclear antibody; BAFF: B-lymphocyte activating factor; CHC: chronic Hepatitis C; CRP: C-reactive
protein; ESR: Erythrocyte Sedimentation Rate; M: man; NSAIDs: Non-steroidal anti-inflammatory drugs; PEG-IFN: Pegylated interferon; RF: rheumatoid factor;
RIB: ribavirin; W: woman; +: positive; ↑: increased.
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Ghent, Belgium). Liver biopsy showed a chronic active
hepatitis, with Metavir A2 necroinflammatory grading and
F2 fibrosis. FibroScan value was 6.1 kPa. Alanine amino-
transferase (ALT) was over two times the upper limit of
normal; thyroid hormones were normal as well as serum
autoantibodies. After a psychiatric exam, which was nega-
tive for depressive disorders, the patient was considered
eligible for antiviral treatment.
Table 2 illustrates in detail biochemical and virological
parameters prior to antiviral treatment initiation.
In March 2011 antiviral therapy was started with PEG-
IFN-α-2a (180 mcg per week subcutaneously) and ribavi-
rin (1000 mg per day orally). This therapy was prolongedTable 2 Biochemical, virological, histological and
immunological parameters before and after a 24-week
course of PEG-IFN-α-2a and ribavirin in a CHC patient
who developed post-treatment RA
Pretreatment Post-treatment
AST (IU/mL) 66 25
ALT (IU/mL) 84 19
HCV RNA (IU/mL) 660,000 negative





C-reactive protein (mg/dL) 0.35 2.21
Rheumatoid Factor negative positive
Anti-CCP Antibodies (IU/ml) negative 860
Antinuclear Antibodies negative 1/320
Anti-dsDNA Antibodies negative negative
Cryoglobulin negative negative
ALT: alanine aminotransferase; AST: aspartate aminotransferase;
anti-CCP: anti-cyclic citrullinated protein; CHC: cronic hepatitis C;
dsDNA: double-stranded DNA; RA: rheumatoid arthritis.for as long as 24 weeks. HCV-RNA became negative by
the fourth week and persisted undetectable up to treat-
ment completion. Similarly, alanine aminotransferase
(ALT) persistently normalized within the first 3 weeks of
treatment. Treatment was well tolerated, with the excep-
tion of flu-like symptoms, easily controlled by paraceta-
mol, and a mild thrombocytopenia (platelet count nadir
of 88,000/μl). In September 2011, the patient started the
post-treatment follow up which confirmed the persist-
ence of normal ALT and negative HCV RNA throughout
48 weeks up to September 2012. In September 2012, a
new liver biopsy showed a mild reduction of Metavir
grading and staging (A1 and F1, respectively).
Nine weeks after the cessation of PEG-IFN and ribavi-
rin (November 2011), the patient developed symmetrical
polyarthritis, with pain and edema in the wrists, knees,
shoulders and metacarpophalangeal joints, associated
with prolonged morning stiffness. Distal interphalangeal
joints were spared. Hand X-ray showed no remarkable
findings, but magnetic resonance imaging (MRI) detected
bone erosions with juxta-articular osteopenia in wrist,
knee and hand joints. Laboratory exams revealed a white
blood cell count (WBC) of 7,200 cells/μl, haemoglobin
level was 12.8 g/dL, creatinine was 0.9 mg/dL. Post-
treatment biochemical, virological and immunological
data are summarized in Table 2.
A diagnosis of rheumatoid arthritis (RA) was made
on the basis of clinical features, MRI evidence of juxta-
articular bone erosions, Rheumatoid Factor (RF) and
anti-cyclic citrullinated peptide (anti-CCP) antibody
positivity.
The patient was initially treated with prednisone 25 mg/
day orally and Nonsteroidal Anti-inflammatory Drugs
(NSAIDs) for as long as two months; in April 2012 he was
switched to methotrexate (6 mg/week) and sulfasalazine
(2 grams/day), due to the persistence of joint pain, obtain-
ing a quick favorable response to treatment.
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HCV-related inflammatory arthritis has been described
as falling into two subsets. One subset is associated with
mixed cryoglobulinemia and is usually monoarticular
[15]. The other subset is a symmetrical RA-like polyar-
thritis lacking juxta-articular erosions and rheumatoid
nodules [15]. Differently from patients affected with
overt RA, patients with HCV-related arthritis also lack
anti-CCP titers [11,15]. Another relevant characteristic
of HCV-related arthritis resides in the fact that it fre-
quently improves after treatment with IFN-α, even with-
out achieving a complete virological response, possibly as
a consequence of decreased viral load [15].
Standard combination therapy of PEG-IFN-α and ri-
bavirin in CHC subjects is associated with a sustained
virological response (SVR) in more than 50% of patients
[16]. A number of predisposing conditions [17], includ-
ing the presence of a clear-cut liver cirrhosis, could
negatively affect the outcome of such therapy [18]. In
addition, antiviral treatment is accompanied by a wide
variety of possible side effects. The most frequent IFN
side effects, which have been described not only in
CHC, but also in acute hepatitis C [19] and chronic
hepatitis B [20] are flu-like symptoms, hematologic ab-
normalities, such as leukopenia and thrombocytopenia,
and psychiatric changes, such as irritability and depres-
sion. Moreover, immunomodulatory effects of IFN may
lead to the induction or exacerbation of autoimmune
diseases, including psoriasis, thyroiditis, systemic lupus
erythematosus and rarely RA [7,11-14,21-23]. IFN-α
determines a shift of T-lymphocyte responses towards a
T-helper (Th)-1 profile, inhibiting the production of
Interleukin (IL)-10 and stimulating the release of tumor
necrosis factor (TNF)-α and IL-12. In addition, IFN-α has
been found to induce the production of B-lymphocyte
activating factor (BAFF) both in mice with lupus erythe-
matosus [23] and patients with multiple sclerosis [24].
Considering that BAFF levels have been shown to cor-
relate with autoantibody levels and synovitis in a subset
of patients with early RA [25], it may be hypothesized
that BAFF induction, occurring during treatment with
IFN-α, may favor the development of RA in susceptible
individuals. Indeed, Izumi et al. [11] found that BAFF
titers were markedly higher after starting antiviral treat-
ment with IFN plus ribavirin in comparison with pre-
treatment values.
Only 4 cases of RA associated with recombinant or
Pegylated-IFN-α treatment for CHC have been previously
reported in the literature [11-14] (Table 1). In the afore-
mentioned case report of Izumi et al. [11], RA developed
three months after cessation of antiviral treatment,
whereas in the other reports [12-14] RA occurred during
treatment, with an interval ranging from 10 to 42 weeks of
therapy. PEG-IFN-α was administered in 3 of 4 cases,whereas in the remaining case recombinant IFN-α-2b was
used [12]. Anti-CCP antibodies tested positive only in two
of four case reports [11,14]. Of interest, Ionescu et al. [13]
presented the case of a 45-year-old woman who had devel-
oped RA during treatment with PEG-IFN-α-2b and ribavi-
rin, whose retreatment with PEG-IFN α-2a and ribavirin
for relapsing CHC caused the reappearance of RA. In our
case, both the detection of anti-CCP antibodies and the
presence of erosive disease allowed to distinguish RA from
typical HCV-related arthritis. In addition, our patient de-
veloped arthritis after cessation of PEG-IFN-α plus ribavi-
rin treatment, when HCV RNA was no longer detectable.
Therefore, a diagnosis of IFN-induced RA was more likely
than one of HCV-associated arthritis.
In conclusion, we report a case of RA occurring after a
successful course of PEG-IFN-α plus ribavirin for the
treatment of CHC. The present case suggests that bio-
logical agents, affecting the cytokine network, may
work as triggering factors for the development of RA.
Before treating CHC patients with PEG-IFN-α and riba-
virin, screening for anti-CCP levels may be considered;
in addition, a close surveillance for the occurrence of
autoimmune phenomena during and after treatment
should be worthy, for early diagnosis and adequate clin-
ical management.
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